[Complex echography in the evaluation of the efficiency of treatment for some forms of lymphoproliferative diseases in the lesion of lymph nodes of the abdomen and retroperitoneal space].
A complex ultrasound study of the abdominal and retroperitoneal lymph nodes afflicted by a lymphoproliferative process was made in 33 primary and 20 secondary (pretreated) patients prior to specific therapy and during treatment. The basic echographic signs of their involvement in the pathological process were as follows: higher dimensions, hypoechogenicity, and intranodal vascularization. The lymphoma-affected lymph nodes (in 10 patients) featured rich blood supply with color signals both in the center and around the periphery of a lymph node. The first changes in the diseased lymph nodes as a reduction in the number of intranodal vessels and/or vascular fragments were noted on echograms (in both primary and secondary patients) three days after the initiation of specific therapy if the latter was effective. The node became hypovascular or avascular; there was a rise in the echogenicity of abnormal lymph nodes. During continued antitumor treatment, echographic monitoring revealed regression of the involved lymph nodes or stabilization of the pathological process in 79% of the primary patients and in 80% of the secondary ones. In the remaining patients, the disease progressed in 21% of the primary patients and in 20% of the secondary ones.
Miniukova
T N
TN
D000005:Abdomen; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging*; D008232:Lymphoproliferative Disorders / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging / Q000503:physiopathology; D011379:Prognosis; D012187:Retroperitoneal Space; D012720:Severity of Illness Index; D018615:Ultrasonography, Doppler, Color / Q000379:methods*
D000970:Antineoplastic Agents